bezuclastinib
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2024 (NCT06208748)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1[nH]nc(C(=O)Nc2cnc3[nH]c(-c4ccccc4)cc3c2)c1C- Mol. weight
- 331.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095229 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06208748 | Phase 2 | Jul 31, 2024 | Cogent Biosciences, Harvard University, Sarcoma Alliance for Research through Collaboration |
| NCT06948955 | N/A | — | Cogent Biosciences |
| NCT06915766 | N/A | — | Cogent Biosciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cogent Biosciences | For profit | 3 | 2 | 2 | 2024 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sarcoma Alliance for Research through Collaboration | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1